Related Experiment Videos
[Asymptomatic osteonecrosis of the hip in HIV-infected patients]
José Luis Lamas1, Antonio Ocampo, César Martínez-Vázquez
1Unidad de Enfermedades Infecciosas, Servicio de Medicina Interna, Complejo Hospitalario Universitario de Vigo, Hospital Xeral, Universidad de Santiago de Compostela, Vigo, Pontevedra, España.
Insights
The prevalence of silent osteonecrosis of the hip in human immunodeficiency virus (HIV)-infected patients is 4.1%. Key risk factors include corticosteroid treatment, lower CD4 counts, and AIDS-defining illness.
Area of Science:
- Orthopedics
- Infectious Diseases
- Radiology
Context:
- Osteonecrosis (ON) of the hip is a known complication in patients with human immunodeficiency virus (HIV).
- Potential risk factors include corticosteroid use, dyslipidemia, alcoholism, lipodystrophy, antiretroviral drugs, and HIV infection itself.
- Evaluating silent ON in HIV patients is crucial for understanding disease progression and management.
Purpose:
- To determine the prevalence of asymptomatic osteonecrosis (ON) of the hip in HIV-infected patients.
- To investigate the association between ON of the hip and various risk factors in this population.
Summary:
- A magnetic resonance imaging (MRI) study was conducted on 97 HIV-infected patients (aged 20-70) who met specific inclusion criteria.
- Osteonecrosis of the hip was detected in 4 patients (4.1%), all of whom were male.
- Significant differences were observed in CD4 lymphocyte nadir, CDC stage C prevalence, and prior corticosteroid treatment between patients with and without ON.
Impact:
- The study identified a 4.1% prevalence of asymptomatic osteonecrosis of the hip in HIV-infected individuals.
- Corticosteroid treatment, lower CD4 lymphocyte nadir, and AIDS-defining disease emerged as significant risk factors.
- Antiretroviral treatment did not show an association with osteonecrosis in this cohort.
Background:
Osteonecrosis (ON) of the hip in human immunodeficiency virus (HIV)-infected patients has been related to corticosteroid use, dyslipidemia, alcoholism, lipodystrophy, antiretroviral drug use, and HIV infection, itself. The aim of this study was to evaluate the prevalence of silent ON of the hip in HIV-infected patients and its association with several risk factors.
Methods:
From a total of 1200 patients followed up at the HIV clinic of Xeral-Cies Hospital in Vigo (Spain), we selected those diagnosed with HIV infection before January 2006, aged 20-70 years, who came to the clinic during the period of March to May 2008. Patients with a diagnosis of ON of the hip and those with current symptoms were excluded. A magnetic resonance imaging (MRI) study of the hips was performed.
Results:
Ninety-seven Caucasian patients (68 men) with a median age of 44 years were included. ON of the hip was detected in 4 patients (4.1%), with bilateral involvement in 2 patients. All 4 patients were men, with a median age of 44.5 years. Several risk factors for ON of the hip were recorded in each patient. CD4 lymphocyte nadir (P=0.034), percentage of patients with CDC stage C (P=0.039), and number of patients with previous corticosteroid treatment (P=0.042) were significantly different between patients with ON of the hip and those with normal MRI findings.
Conclusions:
The prevalence of asymptomatic ON of the hip in HIV-infected patients was 4.1%. The most important risk factors for developing this condition were corticosteroid treatment, lower CD4 lymphocyte nadir, and AIDS-defining disease. Antiretroviral treatment was not associated with osteonecrosis.
Related Concept Videos
Cryptococcal Meningitis
Sexually Transmitted Infections
Osteoclasts in Bone Remodeling
Retrovirus Life Cycles
Bone Disorders
Bone deposition is also affected by the levels of sex hormones like estrogen and testosterone that promote osteoblast activity and bone matrix synthesis. When the level of these hormones decreases due to aging, it causes a reduction in bone deposition. As a result, bone resorption by osteoclasts...